ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 724

Are Traditional Biomarkers of Lupus Associated with Renal Pathology in Lupus Nephritis?

Kelly Liang1, Kimberly P. Liang2, Yaming Li3, Alex Hurd3, Douglas Landsittel4 and Sheldon Bastacky5, 1Medicine, Renal-Electrolyte Division, University of Pittsburgh, Pittsburgh, PA, 2Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 3Biostatistics, University of Pittsburgh, Pittsburgh, PA, 4Biomedical Informatics, University of Pittsburgh, Pittsburgh, PA, 5Pathology, University of Pittsburgh, Pittsburgh, PA

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Biomarkers, biopsies, Lupus, lupus nephritis and renal disease

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Systemic Lupus Erythematosus – Clinical Poster I: Clinical Manifestations and Comorbidity

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

Traditional biomarkers for systemic lupus erythematosus (SLE) and lupus nephritis (LN) include serum creatinine (Cr), complement levels (C3/C4), double-stranded DNA antibody (dsDNA), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), urine red blood cells (uRBC), and urine protein/Cr ratio (uPCR). However, these clinical parameters have limited specificity for active LN and are inconsistent predictors of renal pathology. Whether these biomarkers are associated with LN class has important implications in therapeutic decision-making. The objectives of this study are: 1) to determine whether these biomarkers are associated with LN on renal biopsy; 2) to determine whether they can distinguish between LN classes; and 3) to assess correlation between these biomarkers and activity and chronicity indices on renal biopsy.

Methods:

Using the University of Pittsburgh Health Sciences Tissue Bank (HSTB) and Renal Pathology Department stored biopsy specimens, we identified 37 cases of LN diagnosed on renal biopsy from 2010-2016. Using the electronic database, we obtained LN classes and biomarkers checked within a few days to a month of biopsy date for each sample. Descriptive summaries, correlations, Fisher’s exact test, and rank-sum tests were used to evaluate the relationship between the biomarkers and LN.

Results:

Of the 37 LN samples, 1 had class I, 3 had class II, 10 had class III, 15 had class IV, and 13 had class V (5 with isolated class V) LN. Excluding samples with missing data, 14 (47%) had Cr >1.3 mg/dL. There were 17 (56.7%) with low C3, 18 (60.0%) with low C4, and 16 (59.3%) with dsDNA positivity. Of the 11 samples negative for dsDNA, 8 had class III or IV, and 3 had class I, II, or V LN. Overall mean ± SD ESR was 53.3 ± 35.6 mm/h and CRP was 1.2 ± 2.5 mg/dL. Hematuria was variably reported, but only 11 (37.9%) had >5 RBC/hpf on urinalysis. Mean ± SD uPCR was 2.6 ± 2.9 mg/g Cr. Comparison of biomarkers between classes III and IV vs. other classes (I, II, V, and II+V) showed significantly greater proportion with low C3 (66.7% vs. 16.7%; p=0.027) and significantly higher activity index (7.2 ± 3.8 vs. 1.0 ± 0.7; p=0.002) in class III-IV vs. other classes. Comparison of biomarkers for class V only vs. classes III and IV with or without class V (III, IV, III+V, and IV+V) showed significantly lower proportion with low C3 (0.0% vs. 66.7%; p=0.008) and significantly lower activity index (0.5 ± 0.7 vs. 7.2 ± 3.8; p=0.034) in class V vs. class III-IV. There was no significant correlation between any biomarker and activity index. There was borderline significant correlation between CRP (rho -0.4, p=0.058) and uPCR (rho 0.4, p=0.057) and chronicity index.

Conclusion:

Traditional biomarkers of SLE and LN are imperfect predictors of LN class on renal biopsy. Surprisingly, only C3 was significantly different between LN classes, and none were significantly correlated with activity and chronicity indices. Because clinical laboratory and urine biomarkers do not distinguish LN classes well, renal biopsy is necessary to reliably diagnose LN class. Given the lack of associations between traditional biomarkers and renal pathology, more specific LN biomarkers are urgently needed.


Disclosure: K. Liang, None; K. P. Liang, None; Y. Li, None; A. Hurd, None; D. Landsittel, None; S. Bastacky, None.

To cite this abstract in AMA style:

Liang K, Liang KP, Li Y, Hurd A, Landsittel D, Bastacky S. Are Traditional Biomarkers of Lupus Associated with Renal Pathology in Lupus Nephritis? [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/are-traditional-biomarkers-of-lupus-associated-with-renal-pathology-in-lupus-nephritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/are-traditional-biomarkers-of-lupus-associated-with-renal-pathology-in-lupus-nephritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology